The cutting-edge technology used in COVID-19 shots may lead to new treatments for other diseases. But some conservatives are ...

Fintel reports that on March 13, 2025, Citigroup initiated coverage of Moderna (NasdaqGS:MRNA) with a Neutral recommendation.

The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how ...

Mainz Biomed Enters into Exclusive Licensing Agreement for the Portfolio of mRNA Biomarkers, with Continued Development of ...

The MP leading a government review of resource management has even questioned whether Slovakia ever had a pandemic.

It is five years to the day since schools, colleges and childcare facilities in Ireland closed due to COVID-19.

The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how to increase uptake. mRNA vaccine research may be on the chopping block, too.

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in ...

The second group, so-called "Constrained Losers," are those hard-to-short stocks that have lost the most over the trailing year. The professors found that these stocks also lag the market, but for a ...

South African universities are losing vital scientific talent due to chronic research underfunding, forcing researchers to ...

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

Vaccine hesitancy and higher rates of school vaccine exemptions increases the risk of outbreaks of preventable diseases, creating a significant health risk for vulnerable populations.